Jci_page_head_homepage_01 Jci_page_head_homepage_02
Heidi Koegel, Lukas von Tobel, Matthias Schäfer, Siegfried Alberti, Elisabeth Kremmer, Cornelia Mauch, Daniel Hohl, Xiao-Jing Wang, Hans-Dietmar Beer, Wilhelm Bloch, Alfred Nordheim, Sabine Werner
Published in Volume 119, Issue 4
J Clin Invest. 2009; 119(4):899–910 doi:10.1172/JCI37771
Abstract | Full text | PDF | Supplemental material
Options: View larger image (or click on image)
Medium
Figure 7
siRNA-mediated downregulation of SRF in primary human keratinocytes disrupts the actin cytoskeleton and affects cell adhesion but not proliferation.

(A) SRF protein is efficiently downregulated in primary human keratinocytes as shown by Western blot analysis. Scrambled siRNA and siRNA against Bid served as controls. GAPDH was used as a loading control. (B) Schematic representation of SRF mRNA. Black bars indicate siRNA-binding sites. (C) Immunofluorescence analysis of SRF (red) shows reduced nuclear staining in SRF siRNA–treated keratinocytes. Costaining with phalloidin-FITC (green) revealed reduced cell size (see upper panels) and less filopodia (see lower panels) in SRF1 and SRF2 siRNA–treated keratinocytes. Scale bars: 20 μm (upper panels); 5 μm (lower panels). (D) Western blot analysis showing expression of SRF, E-cadherin, γ-catenin (plakoglobin), and β-actin in keratinocytes treated with scrambled or SRF siRNAs. siRNA against an unrelated protein (caspase-5) was used as an additional control. (E) Adhesion efficiency of SRF siRNA–treated keratinocytes is significantly reduced (n = 3). Error bars show mean ± SEM, *P = 0.021 (Bid/SRF1); P = 0.038 (scrambled/SRF1); **P = 0.005 (Bid/SRF2); P = 0.009 (scrambled/SRF2), ANOVA with Bonferroni’s post hoc test. (F) BrdU incorporation was analyzed in keratinocytes that had been treated for 3 days with SRF siRNAs or with control siRNAs (n = 3 wells per treatment group; 10 microscopic fields per dish were counted). Error bars show mean ± SEM. No significant difference was detected using ANOVA with Bonferroni post hoc test.